Skip to main content
Report File
Date Issued
Submitting OIG
Department of Health & Human Services OIG
Other Participating OIGs
Department of Health & Human Services OIG
Agencies Reviewed/Investigated
Department of Health & Human Services
Components
Centers for Medicare and Medicaid Services
Report Number
OEI-02-22-00160
Report Type
Inspection / Evaluation
Number of Recommendations
4
Questioned Costs
$0
Funds for Better Use
$0

Open Recommendations

This report has 3 open recommendations.
Recommendation Number Significant Recommendation Recommended Questioned Costs Recommended Funds for Better Use Additional Details
23-E-02-028.01 No $0 $0

CMS should monitor the use of buprenorphine and share information, as appropriate, with Departmental partners.

23-E-02-028.02 No $0 $0

CMS should inform providers about buprenorphine use and the low risk of diversion to encourage providers to treat more Part D enrollees who have opioid use disorder.

23-E-02-028.03 No $0 $0

CMS should take steps to inform providers about the availability of buprenorphine combination products in Part D, which can minimize the risk of misuse and diversion.

Department of Health & Human Services OIG

United States